Results

Total Results: 2,146 records

Showing results for "factor".

101. Data Points #14: Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/dcis-endocrine-therapy/research
     September 13, 2012 - In addition, about 60,000 women were diagnosed with ductal carcinoma in situ (DCIS), a possible risk factor

102. Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/stroke-afib-update/research-2018
     October 30, 2018 - include new antithrombotic strategies, devices, and oral anticoagulants (oral direct thrombin inhibitors, factor

103. #06 Developmental Delays ADHD, and Autism (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1312.pdf
     December 01, 2013 - Oxytocin factor - 30 ml nasal spray. [internet]. Amazon.com, Inc. … Available: http://www.amazon.com/Oxytocin- Factor-30-Nasal-Spray/dp/B007K8LTD2. 30. … Oxytocin factor. [internet]. ABC Nutriceuticals [accessed 2013 Nov 21]. [2 p]. … startswith=oxytocin&x=0&y=0 http://www.fda.gov/ http://www.amazon.com/Oxytocin-Factor-30-Nasal-Spray/ … dp/B007K8LTD2 http://www.amazon.com/Oxytocin-Factor-30-Nasal-Spray/dp/B007K8LTD2 http://tryoxytoday.com

104. Slide 1
     effectivehealthcare.ahrq.gov/sites/default/files/estimation-and-reporting_chapter-3.pptx
     January 01, 2013 - disease, the effect of exposure on outcome (treatment effect) differs according to the level of the other factor … that the effect of exposure on outcome (treatment effect) differs according to the level of the other factor … treatment effect may be required even when the variable that modifies treatment effect is not a risk factor

105. Maternal Morbidity and Mortality (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/mmm-draft-protocol_0_0.pdf
     November 04, 2021 - Indigenous, People of Color (BIPOC) individuals.13 Important to recognize is that race itself is not a risk factor … We will use the ROBINS-E tool, which is designed specifically to address risk factor research.32, 33 … when 1) at least two studies with sufficiently similar designs and populations examined the same risk factor … identify people followed in a study to help understand who may be similarly be subject to the risk factor … or logistic regression or "near miss").ti,ab,kw. 775160 10 (risk* adj3 (assess* or factor

106. Interventions for Preventing Cognitive Decline, Mild Cognitive Impairment, and Alzheimer’s Disease | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/cognitive-decline/research-protocol
     March 23, 2016 - addressing nutrition, physical activity, cognitive training, social activity, and/or vascular risk factor … The etiology may involve more than one risk factor and interventions may have several components. … interventions for preventing dementia have looked at only the one-to-one relationship with a single risk factor … characteristics (i.e., age, sex, race/ethnicity, family history, education, socio-economic status, risk factor … characteristics (i.e., age, sex, race/ethnicity, family history, education, socio-economic status, risk factor

107. PowerPoint Presentation (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/medical-test-reviews-applicability.ppt
     June 01, 2012 - Example: Slice thickness is a relevant factor for assessing the applicability/accuracy of cardiac magnetic … Principle 1: Identify Important Contextual Factors (2 of 10) The first contextual factor is spectrum … Principle 1: Identify Important Contextual Factors (3 of 10) The second contextual factor concerns where … Principle 1: Identify Important Contextual Factors (4 of 10) The third contextual factor concerns the … Principle 1: Identify Important Contextual Factors (9 of 10) The sixth and final contextual factor to

108. PowerPoint Presentation (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/medical-test-reviews-applicability.ppt
     June 01, 2012 - Example: Slice thickness is a relevant factor for assessing the applicability/accuracy of cardiac magnetic … Principle 1: Identify Important Contextual Factors (2 of 10) The first contextual factor is spectrum … Principle 1: Identify Important Contextual Factors (3 of 10) The second contextual factor concerns where … Principle 1: Identify Important Contextual Factors (4 of 10) The third contextual factor concerns the … Principle 1: Identify Important Contextual Factors (9 of 10) The sixth and final contextual factor to

109. Topic Suggestion Description | Effective Health Care Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/comparative-effectiveness-of-conventional-computed-tomography-ct-multidetector-computed-tomography-mdct-ct-colonography-fludeoxyglucose-positron-emission-tomography-fdg-pet-or-fdg-petct-magnetic-resonance-imaging-mri-ultrasou
     December 27, 2011 - Mesorectal involvement in the circumferential margin (CRM) is an important factor in deciding the need

110. Effective Health Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0398_06-17-2008.pdf
     January 01, 2008 - )  Anemia in patients with end-stage renal disease (ESRD) is a risk factor for increased mortality

111. What is the comparative effectiveness of conventional CT, MDCT (including “virtual CT bronchoscopy”), PET/PET-CT, and MRI for the diagnosis or pretreatment staging of small cell and non-small cell lung cancer? | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/what-is-the-comparative-effectiveness-of-conventional-ct-mdct-including-virtual-ct-bronchoscopy-petpet-ct-and-mri-for-the-diagnosis-or-pretreatment-staging-of-small-cell-and-non-small-cell-lung-cancer
     December 28, 2011 - socioeconmically disadvantaged populations are especially at risk due to high rates of smoking, a strong risk factor

112. Atrial-Fibrillation-Ablation Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/atrial-fibrillation-ablation_surveillance.pdf
     May 16, 2013 - recurrence rates, three studies showed that gender was either a significant predictor or protective factor … vs. no AF recurrence Female gender: HR=0.092, 95% CI: 0.022, 0.386 (female gender as a protective factor … AF recurrence) HR=0.58, 95% CI: 0.36, 0.94 [MVA] (absence of coronary disease as a protective factor … No AF termination 38(5) vs. 44(8); smaller LA diameter [mm] as a protective factor against AF, MVA … against AF recurrence, MVA) OR=0.051, 95% CI: 0.008, 0.338 (PAF as a protective factor against

113. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/thromboembolism-update-executive-170622.pdf
     June 01, 2017 - molecular weight heparin (LMWH), vitamin K antagonists (VKA), antithrombin III-mediated selective factor … Xa inhibitors, direct factor Xa inhibitors (FXaI), bivalent and univalent direct thrombin inhibitors … Mechanical prophylaxis aims to minimize stasis, the principal putative factor resulting in venous thrombosis … the searches from the 2012 VTE report and added additional 4 terms for new treatments (e.g., factor … VIII inhibitors (FEI), factor Xa inhibitors (FXaI), factor XI inhibitors (FXIi), direct thrombin inhibitors

114. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/thromboembolism-update-executive-170622.pdf
     June 01, 2017 - molecular weight heparin (LMWH), vitamin K antagonists (VKA), antithrombin III-mediated selective factor … Xa inhibitors, direct factor Xa inhibitors (FXaI), bivalent and univalent direct thrombin inhibitors … Mechanical prophylaxis aims to minimize stasis, the principal putative factor resulting in venous thrombosis … the searches from the 2012 VTE report and added additional 4 terms for new treatments (e.g., factor … VIII inhibitors (FEI), factor Xa inhibitors (FXaI), factor XI inhibitors (FXIi), direct thrombin inhibitors

115. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/tinnitus_research-protocol.pdf
     February 22, 2012 - traditional Chinese medicinal treatment used to increase blood flow, inhibit the platelet-activating factor … basis of the design or analysis a) study controls for _______________ (Select the most important factor … control for a second important factor.) … ) * b) study controls for any additional factor * (This criteria could be modified to indicate specific … - Appropriate methods are used if imputation is used for missing prognostic factor ☐

116. Methods Guide for Medical Test Reviews - Editorial (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guide-editorial_methods.pdf
     July 01, 2012 - fields of general internal medicine, family practice, nursing, and mental health, the average impact factor … for systematic reviews was 26.5.1 In contrast, the mean impact factor for the top 40 general medical

117. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ace-inhibitor-arb-2007_executive.pdf
     January 01, 2007 - In addition to being the number one attributable risk factor for death throughout the world, hypertension … Risk factor reduction and other Moderate (lipid There were no consistent differential effects of ACEIs

118. Cystic-Fibrosis-Hgh Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cystic-fibrosis-hgh_surveillance.pdf
     August 01, 2012 - safety concerns • Evaluation of the safety and efficacy of recombinant human Insulin-like Growth Factor-I … However, we also accepted for review studies of insulin-like growth factor I for the treatment of cystic … [IGF-I] increases over 100 ng/ml or insulin –like growth factor binding protein-3 [(IGFBP-3] decreases … I; IGFBP insulin-like growth factor binding protein; LBM lean body mass; MHRA Medicines and Healthcare … [IGF-I] increases over 100 ng/ml or insulin –like growth factor binding protein-3 [(IGFBP-3] decreases

119. Methods Research Report - Meta-Analytical Statistical Inferences for Continuous Measure Outcomes as a Function of Effect Size Metric and Other Assumptions (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/statistical-inference_research.pdf
     April 01, 2013 - • Because the main factor that affected estimates was the magnitude of the correlation between the … these indexes present opposite patterns to their corresponding versions including the correlation factor … mean difference; db_nonr = Becker’s standardized mean difference without including the correlation factor … for a total ES in different metrics, examining those that can include vs. exclude the correlation factor … When the correlation factor is included, all exhibit similar trends, with better performance when ρ

120. Ebell_Presentation_REVISED_FINAL (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/use_of_handheld_ebell_presentation.pdf
     January 01, 2009 -  based  on:   o Counting  (i.e.  1  point  per  clinical  finding  or  risk  factor